154.06
前日終値:
$155.92
開ける:
$155.92
24時間の取引高:
812.95K
Relative Volume:
0.65
時価総額:
$15.66B
収益:
$3.10B
当期純損益:
$668.60M
株価収益率:
23.69
EPS:
6.5044
ネットキャッシュフロー:
$831.30M
1週間 パフォーマンス:
+0.98%
1か月 パフォーマンス:
-15.74%
6か月 パフォーマンス:
+16.49%
1年 パフォーマンス:
+10.88%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences Inc
|
154.06 | 15.55B | 3.10B | 668.60M | 831.30M | 6.5044 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.03 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
10.11 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.44 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
77.34 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
515.46 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Zacks Investment ResearchGlobes - Globes - Israel Business News
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last? - Yahoo Finance
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth? - Yahoo Finance
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - Yahoo Finance Singapore
Neurocrine Biosciences (NBIX) Could Be 28% Undervalued On Fresh INGREZZA Data - simplywall.st
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
GlobesIsrael Business News - גלובס
Neurocrine Biosciences Rings the Nasdaq Stock Market Opening Bell - Nasdaq
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? - Yahoo Finance
Neurocrine Biosciences Rings the Opening Bell - Nasdaq
Neurocrine Biosciences (HAM:NB3) Cyclically Adjusted Price-to-FCF : (As of Aug. 16, 2026) - GuruFocus
S&CO Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.93 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V. - MarketBeat
Can Neurocrine (NBIX) Turn Patient-Centric INGREZZA Data Into Durable Neurology Leadership? - simplywall.st
NBIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Summit Global Investments Invests $4.96 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths - The Business Journals
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters
Neurocrine Biosciences Inc (NBIX) Shares Fall 3.6% -- What GF Sc - GuruFocus
Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Vykat Safety Concerns Take Shine Off Neurocrine Soleno Buy - insights.citeline.com
Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating - marketscreener.com
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo Finance
NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Yahoo Finance
Neurocrine Biosciences Inc (NBIX) Shares Fall 3.4% -- What GF Sc - GuruFocus
Why is Neurocrine Biosciences stock sliding today? By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) Dips 3%: Stock Holds Above Key Support at $156.99Quality Factor - Vinanet
Why Neurocrine Biosciences (NBIX) Stock Is Down Today - Quiver Quantitative
What's Going On With Neurocrine Biosciences Stock On Wednesday? - Benzinga
Neurocrine down on safety events linked to Vykat (NBIX:NASDAQ) - Seeking Alpha
Neurocrine Biosciences Shares Drop Amid Vykat Safety Reports - StockInvest.us
Neurocrine Biosciences shares fall amid Vykat safety concerns - Yahoo Finance
Neurocrine Biosciences stock falls on Vykat safety concerns By Investing.com - Investing.com Canada
Neurocrine Biosciences stock falls on Vykat safety concerns - Investing.com
Neurocrine study shows Ingrezza improved tardive dyskinesia symptoms - Investing.com
Neurocrine's INGREZZA Study Reports Better Daily Function in TD - Stock Titan
Why is Neurocrine Biosciences stock down today? By Investing.com - Investing.com Australia
Handelsbanken Fonder AB Has $34.70 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Liquidity Mapping Around (NBIX) Price Events - Stock Traders Daily
Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing? - Sahm
Neurocrine Initiates Phase I Trial of Triple Agonist NBIP-’1968 for Obesity - BioPharma APAC
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: A 30% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Bank of America Corp DE Boosts Holdings in Neurocrine Biosciences, Inc. $NBIX - marketbeat.com
Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Neurocrine Biosciences, Inc. (NB3.F) Analyst insights, Price targets and Recommendations - Yahoo Finance Australia
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers - MarketBeat
Healthcare Stocks Investors Are Watching For Steady Demand After Weak US Jobs Data - Sahm
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):